Direct Haler A/S | Managing Director & Co-founder | Drug Delivery Systems | Combination Products | Industry sale Exit
Our family founded Direct-Haler A/S, a science-based start-up, developing and commercializing pulmonary and nasal drug delivery device technology (DDS). Business development was the core of my responsibility, concluding with a successful industry sale exit. Link to video on the Direct Haler case.
We developed and operated the company as an international virtual organization. We scouted, created and matured a portfolio of business opportunities for out-licensing to pharma. This has refined our skills in creative and analytical aspects of business development:
• Gathered and analyzed market insight
• Developed commercial strategy and Business cases for each terapeutic application area
• Developed IPR strategy
• Developed invitro and invivo clinical DDS documentation
• Established DDS promotion “packages”
• Identified potential pharma partners and opened dialogue
• Invited speaker at industry conferences
• Negotiated partnership and licensing agreements
• 2009 Frost & Sullivan European Drug Delivery Devices Product Differentiation Innovation of the Year Award
• Re-established aggregate product portfolio and DDS assets after discontinued licensing agreement: Three respiratory off-patent drugs in Phase I to III, two DDS devices with issued patents in 40+ countries and invitro & invivo technical and acceptability studies.
In 2010, all the drug delivery activities and assets were acquired by Trimel Pharmaceuticals (now Acerus Pharmaceuticals) Canada. I managed the complete asset-based transaction with a team of legal-, patent-, accounting- and corporate finance advisors:
• Developed Teaser, Information Memorandum and Management presentation
• Established virtual Data Room
• Negotiated Term-sheet
• Negotiated industry sale exit contracts
• Planned and completed transfer of assets